Revoking PNTR for China would move Chinese imports onto an average effective Column 2 tariff rate of 38.9 percent, helping rebalance trade, restore domestic production capacity, and reduce strategic dependence on an increasingly adversarial economic system.
CPA welcomes new proposals from the Food and Drug Administration (FDA) aimed at rebuilding domestic generic drug manufacturing, strengthening oversight of foreign pharmaceutical production, and improving supply chain transparency.
The report finds that the CPA Domestic Market Share Index (DMSI) – which measures the share of U.S. demand served by domestic producers – rebounded in 2025 as Section 232 tariffs and other industrial policies began to reshape the competitive landscape for American industry.
Suniva’s expansion highlights the critical importance of rebuilding the domestic crystalline silicon photovoltaic (PV) supply chain—particularly solar cell manufacturing, one of the most strategically important segments of U.S. energy production.
The investment is clear evidence that U.S. trade policy is driving a resurgence in domestic production and job creation. This new investment underscores Whirlpool Corp.’s long-standing commitment to the U.S. market and creating high-quality American jobs.
Section 232 tariffs remain a cornerstone of U.S. industrial policy, particularly in sectors tied to infrastructure, energy, and defense. This proclamation reinforces their role as a long-term tool to increase domestic capacity utilization, reduce import dependence, and support a resilient industrial base.
Today’s action is a meaningful step toward restoring America’s ability to produce critical pharmaceuticals and APIs.
America’s healthcare system cannot remain dependent on fragile and subsidized foreign supply chains for generic pharmaceuticals and other critical countermeasures that are fundamental to patient care.
The report finds that China has consolidated global dominance in the midstream stages of battery supply chains—refining and chemical conversion—giving the Chinese Communist Party significant influence over pricing, supply availability, and industrial investment.
This bipartisan letter from the Senate Banking Committee is a powerful signal that Congress is finally taking seriously what CPA has been warning about for years: the Chinese Communist Party has been exploiting America’s capital markets to fund its military modernization, underwrite its surveillance state, and enrich entities engaged in genocide, forced labor, and espionage — all with American investor capital.
